Detail
| LncRNA Name | SPRY4-IT1 |
| Synonyms | SPRY4-IT1, SPRIGHTLY |
| Region | NA Sequence |
| Ensembl | ENSG00000281881 |
| RefSeq | NR_131221 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | cholangiocarcinoma |
| ICD-0-3 | M810/3 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP etc. |
| Sample | cholangiocarcinoma tissues, cell lines (HIBEC, CCLP-1, HuCCT1, Huh-28, KMBC and QBC939) |
| Expression Pattern | up-regulated |
| Function Description | SPRY4-IT1 was abnormally upregulated in CCA tissues and cells, and this upregulation was correlated with tumor stage and tumor node metastasis (TNM) stage in CCA patients. SPRY4-IT1 overexpression was also an unfavorable prognostic factor for patients with CCA. Additionally,SP1 could bind directly to the SPRY4-IT1 promoter region and activate its transcription. Mechanistically, enhancer of zeste homolog 2 (EZH2) along with the lysine specific demethylase 1 (LSD1) or DNA methyltransferase 1 (DNMT1) were recruited by SPRY4-IT1, which functioned as a scaffold.Importantly, SPRY4-IT1 positively regulated the expression of EZH2 through sponging miR-101-3p. |
| Pubmed ID | 29642935 |
| Year | 2018 |
| Title | SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. |
| External Links |
| Links for SPRY4-IT1 | GenBank HGNC lncrnadb Noncode |
| Links for cholangiocarcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.